Teva Pharmaceutical Industries Ltd (NYSE: TEVA), headquartered in Israel, has announced positive results from a Phase III study for Ajovy (fremanezumab) as a preventive treatment for migraine in adult Chinese patients. The study met its primary and all secondary endpoints, demonstrating Ajovy’s efficacy in reducing the number of migraine days per month compared to placebo. The treatment also achieved a 50% reduction in migraine days and a decrease in acute headache medication use over three months following the initial dose. The safety profile of Ajovy was consistent with no unusual signals, aligning with data from overseas trials.
Ajovy is a humanized monoclonal antibody that selectively targets the calcitonin gene-related peptide receptor (CGRP) ligand, preventing its binding to the receptor. CGRP is known to be released during migraine attacks and is believed to contribute to the initiation of these episodes. Ajovy received its first approval in the U.S. in 2018, followed by the EU in 2019. Teva is now looking to introduce Ajovy to China, home to the world’s largest population of migraine sufferers, with an estimated 14.3% of non-elderly adults affected. This move comes after Eli Lilly’s Emgality (galcanezumab), a CGRP-targeted drug, gained approval in China in January this year for migraine prevention. Additionally, Pfizer’s Nurtec (rimegepant), an oral CGRP antagonist for the acute treatment of migraine attacks, was also approved in China during the same month.- Flcube.com
